Approval Overview

Camcevi (leuprorelin mesylate) is a GnRH (gonadotropin-releasing hormone) agonist marketed by Accord Healthcare S.L.U., based in Barcelona, Spain. It received EU-wide marketing authorization from the EMA on May 24, 2022. The approved indication is hormone-sensitive progressive prostate cancer in adult men, including locally advanced and high-risk localized prostate cancer in combination with radiotherapy. GnRH agonists work by continuously stimulating the pituitary gland, suppressing testosterone production, and are a cornerstone of hormonal therapy for progressive prostate cancer. The EMA product number is EMEA/H/C/005034, and the opinion was adopted on March 24, 2022.

Clinical Efficacy

The key clinical trial used in the EMA evaluation involved 137 patients. Results showed that after a single administration, 98.5% (135/137) achieved castration levels of testosterone (less than 50 ng/dL) at week 4. The proportion maintaining castration levels throughout the 48-week follow-up period was 97% (133/137). The most common adverse event was flushing, occurring in more than 50% of patients, with nausea, malaise, fatigue, and injection site reactions also reported. These figures are clinically comparable to the reference medicine, Eligard (same active ingredient, leuprorelin, Tolmar/Astellas), which formed the basis for the EMA's application of a hybrid approval pathway.

Formulation Differentiation

The key competitive advantage of Camcevi is its ready-to-use pre-filled syringe formulation. The reference product, Eligard, requires the mixing of two syringes before administration, which is inconvenient. Camcevi, on the other hand, can be administered directly as a subcutaneous injection every six months without mixing, reducing the risk of preparation errors and improving efficiency in clinical settings. The six-month single administration also helps minimize the frequency of patient visits.

Competitive Landscape

Competing drugs in the European prostate cancer hormone therapy market include Zoladex (goserelin, AstraZeneca), Trelstar (triptorelin, Pfizer), and Eligard (leuprorelin, Tolmar/Astellas). Recently, Orgovyx (relugolix, Myovant Sciences/Pfizer), a GnRH antagonist, entered the European market, threatening the agonist segment with its rapid suppression effect without initial testosterone flare. The global prostate cancer treatment market is approximately USD 15 billion in 2024, and hormone-inhibiting therapies form a core component of the standard of care for progressive prostate cancer. Accord Healthcare is a European subsidiary of Indian Intas Pharmaceuticals and is expanding its penetration into the EU hospital channel through generic and hybrid strategies.

Market Outlook

Europe has the highest incidence of prostate cancer among male cancers, with approximately 450,000 new diagnoses annually. Following EMA approval, price negotiations and reimbursement listings in each EU member state are necessary, with sequential entry into key markets such as Germany, France, and Italy. Based on Accord's European distribution network and the price competitiveness of its hybrid formulation, it is realistic to expect Camcevi to absorb some of the existing Eligard market share, and the increasing trend in prostate cancer diagnoses due to aging will support mid-term demand growth.